Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines.
The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who has received at least two prior platinum-based treatment regimens, has platinum-sensitive disease, and is in a complete or partial response to the most recent platinum-based regimen. In all cases, the patient must have a special clinical need that cannot be met by current licensed available medicines. Patients must be ineligible for Clovis’ ARIEL4 clinical trial or unable to access a participating ARIEL4 site to qualify for Clovis’ early access program.
Questions or inquiries regarding the RAP should be directed to rucaparibaccessEU@caligorrx.com.
About Rubraca ® (rucaparib)
Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in ovarian cancer as well as several additional solid tumor indications. Studies open for enrollment or under consideration include ovarian, prostate, breast, gastroesophageal, pancreatic, lung and bladder cancers. Clovis holds worldwide rights for Rubraca.
In the United States, Rubraca is approved on an accelerated basis as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. In December 2017, the U.S. Food and Drug Administration (FDA) accepted the Company’s supplemental New Drug Application (sNDA) for Rubraca for a second-line or later maintenance treatment indication in ovarian cancer based on the ARIEL3 data. The FDA granted Priority Review status to the application with a Prescription Drug User Fee Act (PDUFA) date of April 6, 2018.
Rubraca is an unlicensed medical product outside of the U.S.
About Early Access Programs
Early Access Programs provide companies with a way to allow ethical access to their pre-license/unlicensed medicines to help patients with unmet medical needs. Access is provided in response to physician requests, in a fully compliant manner, where no alternative treatment options are available.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK. Please visit clovisoncology.com for more information.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements contained in this press release include, among others, statements regarding our expectation of timing for European Commission approval of rucaparib for the treatment indication and the filing of a variation to the MA for a maintenance indication for rucaparib. Such forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from that expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in actions by the FDA, the EMA or other regulatory authorities regarding whether to approve drug applications that may be filed, as well as their decisions that may affect drug labeling, pricing and reimbursement, and other matters that could affect the availability or commercial potential of our drug candidates or companion diagnostics. Clovis Oncology does not undertake to update or revise any forward-looking statements. A further description of risks and uncertainties can be found in Clovis Oncology’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its reports on Form 10-Q and Form 8-K.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants23.4.2018 11:30 | Pressemelding
Biogen (Nasdaq: BIIB) today announced new findings detailing the benefits that SPINRAZA® (nusinersen) demonstrates for both infantile- and later-onset spinal muscular atrophy (SMA) populations, including improvement in motor function as well as increased survival for the most severely affected. These findings are based on interim results from the SHINE open-label extension study and an analysis of SPINRAZA’s effects on mobility and fatigability in later-onset participants from the CS2/CS12 studies. The research will be presented at the American Academy of Neurology (AAN) Annual Meeting on April 21-27, 2018, in Los Angeles, California. “These results reinforce SPINRAZA’s unprecedented and compelling efficacy across a broad range of SMA populations, enabling patients to improve mobility and motor function – and, for the most severely affected, increase their chances of survival,” said Alfred Sandrock, M.D., Ph.D., executive vice president and chief medical officer at Biogen. “We look for
Country Leaders Inspired by ABB’s Breakthrough E-Mobility Technologies23.4.2018 11:06 | Pressemelding
The two leaders, along with ABB CEO Ulrich Spiesshofer, were shown a demonstration of the company’s new high power fast charging solution: the Terra HP EV charging station with a power output of up to 350 kW recharges a car battery in just eight minutes for 200 km reach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180423005618/en/ From left to right: German Chancellor Angela Merkel, Mexican President Enrique Peña Nieto, ABB CEO Ulrich Spiesshofer, First Lady Mrs. Angélica Rivera, Managing Director of ABB Germany Hans-Georg Krabbe, Managing Director of ABB Mexico Vicente Magana (Photo: Business Wire) “This high-power fast charger provides electric vehicles with up to seven times more range in the same charging time than with previous models,” Spiesshofer said. “Together with our comprehensive ABB AbilityTM digital offering, we easily connect chargers to back offices, payment platforms or smart grid systems and offer our cu
Panasonic Launches Off-grid Solutions Projectto Mark Its Centenary23.4.2018 10:07 | Pressemelding
Panasonic Corporation announced it has kicked off a project for people living in off-grid areas that combines educational activities to promote understanding of electricity and provision of the company’s related products. The Off-grid Solutions Project is part of Panasonic’s corporate social responsibility initiatives, celebrating the centennial of the company’s founding this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180423005551/en/ Power Supply Station installed in Indonesia as part of the project (West Kalimantan) (Photo: Business Wire) This new initiative aims to support the creation of a sustainable society where each individual living without access to the power grid can lead an independent life. Panasonic will donate its products such as solar generation and storage systems, provide education and technical training to cultivate human resources, and help develop local business models taking advantage of elec
CORRECTING and REPLACING FlexTrade Launches FlexNOW Execution Management System (EMS)23.4.2018 08:56 | Pressemelding
Quote in sixth paragraph should be attributed to Lucas Howarth, Fund Manager at Wesleyan (sted of Chris Beton, CTO/CRO at Everett Capital Advisors). The corrected release reads: FLEXTRADE LAUNCHES FLEXNOW EXECUTION MANAGEMENT SYSTEM (EMS) – One-Click Deployment System for Hedge Funds and Mini-Primes – – MiFID II Compliant Trading for Equities, Futures & Options – FlexTrade (@FlexTrade) today announced the official release of FlexNOW, an out-of-the-box, broker neutral EMS to address the needs of hedge funds and mini-primes who require a streamlined, multi-asset trading system at the click of a button. Multi-Asset, MiFID II Compliant Trading -- Designed to handle trading for equities, futures and options, FlexNOW is MiFID II compliant; provides connectivity to leading market data providers; easily integrates with any order management system (OMS) via FIX and API; and comes with its own built-in transaction cost analysis functionality. Easy Installation -- According to Rhyd Lewis, FlexNOW
FlexTrade Launches FlexNOW Execution Management System (EMS)23.4.2018 08:00 | Pressemelding
FlexTrade (@FlexTrade) today announced the official release of FlexNOW, an out-of-the-box, broker neutral EMS to address the needs of hedge funds and mini-primes who require a streamlined, multi-asset trading system at the click of a button. Multi-Asset, MiFID II Compliant Trading -- Designed to handle trading for equities, futures and options, FlexNOW is MiFID II compliant; provides connectivity to leading market data providers; easily integrates with any order management system (OMS) via FIX and API; and comes with its own built-in transaction cost analysis functionality. Easy Installation -- According to Rhyd Lewis, FlexNOW Product Manager at FlexTrade UK, FlexNOW’s zero-touch onboarding and installation process gets clients up and running in a matter of minutes. “By combining the one-click installation process with secure, online connectivity, we have greatly reduced the on-boarding lead time for customers,” said Lewis. Streamlined Trading Workflows -- “We developed FlexNOW based o
Limited Edition Skechers D’Lites & Toei Animation One Piece Collection to Launch in Europe23.4.2018 07:00 | Pressemelding
After initially launching in Asia and with an upcoming debut in the United States and Canada, SKECHERS USA, Inc. (NYSE:SKX) is extending its popular anime collaboration to Europe as well with the launch of Skechers X One Piece. The colorful collection unites Toei Animation’s popular anime series with Skechers D’Lites, one of the footwear company’s original styles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180423005239/en/ Skechers launches limited edition One Piece collection in Europe (Photo: Business Wire) “Pairing the iconic long-running anime series One Piece with one of our top heritage styles resonated with our consumers in South Korea and China who have been driving trends for the past few years,” began Michael Greenberg, president of Skechers. “And now fashion moves at light speed, so as influencers around the world had already been embracing Skechers D’Lites and the chunky sneaker trend, we started to see style